The protein kinase C β-specific inhibitor LY379196 blocks TPA-induced monocytic differentiation of HL60 cells

Molecular Carcinogenesis

Volumn 27, Issue 3, 2000, Pages 166-176

  Slosberg, Eric D ^a,b   Yao, Yao ^a   Xing, Fay ^a   Ikui, Amy ^a   Jirousek, Michael R ^c   Weinstein, I Bernard ^a  

^a Columbia University ^*  (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Cell cycle; Growth arrest; Kinase inhibitors

Indexed keywords

LY 379196; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C INHIBITOR; SPHINGOSINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034060569     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(200003)27:3<166::AID-MC3>3.3.CO;2-Q     Document Type: Article

References (65)

1. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of myeloid leukaemic cells in suspension culture. Nature 1977;270:347-349.
2. Breitman T, Selonick S, Collins S. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980;77: 2936-2940.
3. Rovera G, Ob TG, Diamond L. Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 1979;204:868-870.
4. Rovera G, Santoli D, Damsky C. Human promyelocytic leukemia cells in culture different into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 1979;76:2779-2783.
5. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 1978;75:2458-2462.
6. Newburger P, Chovaniec M, Greenberger J, Cohen H. Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J Cell Biol 1979;82: 315-322.
7. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9:3389-3396.
8. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994;9:3397-3406.
9. Wang QM, Luo X, Studzinski GP. Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res 1997;57:2851-2855.
10. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996;56:264-267.
11. Horiguchi-Yamada J, Yamada H, Nakada S, Ochi K, Nemoto T. Changes of G1 cyclins, cdk2, and cyclin A during the differentiation of HL60 cells induced by TPA. Mol Cell Biochem 1994;132:31-37.
12. Akiyama N, Sasaki H, Katoh O, et al. Increment of the cyclin D1 mRNA level in TPA-treated three human myeloid leukemia cell lines: HEL, CMK and HL-60 cells. Biochem Biophys Res Comm 1993;195:1041-1049.
13. Goodnight J, Mischak H, Mushinski JF. Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv Cancer Res 1994;64: 159-209.
14. Borner C, Fabbro D. PKC and cellular transformation. In: Protein kinase C: Current concepts and future perspectives 1992. 1992;297-354.
15. Jaken S, Kiley SC. Protein kinase C isozymes and substrates. Curr Opin Cell Biol 1996;8:168-173.
16. Johannes F-J, Prestle J, Eis S, Oberhagemann P, Pfizenmaier K. PKC μ is a novel, atypical member of the protein kinase C family. J Biol Chem 1994;269:6140-6148.
17. Cacace A, Guagagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993;8: 2094-2104.
18. Housey GM, Johnson MD, Hsiao WL, et al. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell 1988;52:343-354.
19. Castagna M, Takai Y, Kalbuchi K, Sano K, Kikkawa V, Nixhizuka Y. Direct activation of calcium-activated, phospholipid dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982;257:7847-7851
20. Mischak H, Kolch W, Goodnight J, et al. Expression of protein kinase C genes in hemopoietic cells is cell-type-and B cell-differentiation stage specific. J Immunol 1991;147: 3981-3987.
21. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase Cβ-deficient mice. Science 1996; 273:788-791.
22. Hocevar B, Morrow D, Tykocinski M, Fields A. Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. J Cell Sci 1992;101:671-679.
23. Balazovich KJ, Portnow D, Boxer LA, Prochownik EV. Changes in protein kinase C activity are associated with the differentiation of Friend erythroleukemia cells. Biochim Biophys Acta 1987;927:247-255.
24. GuptaRoy B, Cohen CM. Maturation of murine erythroleukemia cells committed to differentiation requires protein kinase C. J Biol Chem 1992;267:15326-15333.
25. Melloni E, Pontremoli S, Michetti M, et al. Protein kinase C activity and hexamethylenebisacetamide-induced erythroleukemia cell differentiation. Proc Natl Acad Sci USA 1987; 84:5282-5286.
26. Melloni E, Pontremoli S, Viotti PL, Patrone M, Marks PA, Rifkind RA. Differential expression of protein kinase C isozymes and erythroleukemia cell differentiation. J Biol Chem 1989;264:18414-18418.
27. Melloni E, Pontremoli S, Sparatore B, et al. Introduction of the β isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells. Proc Natl Acad Sci USA 1990;87:4417-4420.
28. Kiley SC, Parker PJ. Differential localization of protein kinase C isozymes in U937 cells: evidence for distinct isozyme functions during monocyte differentiation. J Cell Sci 1995; 108:1003-10016.
29. Pierce JH, Di Marco E, Cox GW, et al. Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA. Proc Natl Acad Sci USA 1990;87: 5613-5617.
30. Hashimoto K, Kishimoto A, Aihara H, Yasuda I, Mikawa K, Nishizuka Y. Protein kinase C during differentiation of human promyelocytic leukemia cell line, HL-60. FEBS Lett 1990;263:31-34.
31. Macfarlane DE, Manzel L. Activation of the β-isozyme of protein kinase C (PKCβ) is necessary and sufficient for phorbol ester-induced differentiation of HL-60 promyelocytes. J Biol Chem 1994;269:4327-4331.
32. Makowske M, Ballester R, Cayre Y, Rosen OM. Immunochemical evidence that three protein kinase C isozymes increase in abundance during HL-60 differentiation induced by dimethyl sulfoxide and retinoic acid. J Biol Chem 1988; 263:3402-3410.
33. Tonetti DA, Horio M, Collart FR, Huberman E. Protein kinase Cβ gene expression is associated with susceptibility of human promyelocytic leukemia cells to phorbol ester-induced differentiation. Cell Growth Differential 1992;3: 739-745.
34. Tonetti DA, Henning-Chubb C, Yamanishi DT, Huberman E. Protein kinase C-β is required for macrophage differentiation of human HL-60 leukemia cells. J Biol Chem 1994;269: 23230-23235
35. Yang KD, Mizobuchi T, Kharbanda SM, et al. All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood 1994;83:490-496.
36. Homma Y, Henning-Chubb CB, Huberman E. Translocation of protein kinase C in human leukemia cells susceptible or resistant to differentiation induced by phorbol 12-myristate 13-acetate. Proc Natl Acad Sci USA 1986;83:7316-7319.
37. Mitchell RL, Henning-Chubb C, Huberman E, Verma IM. c-fos expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages. Cell 1986;45:497-504.
38. Homma Y, Gemmel MA, Huberman E. Protein kinase C activities with different characteristics, including substrate specificity, from two human HL-60 leukemia cell variants. Cancer Res 1988;48:2744-2748.
39. Bradshaw D, Hill CH, Nixon JS, Wilkinson SE. Therapeutic potential of protein kinase C inhibitors. Agents & Actions 1993;38:135-147.
40. Grunicke HH, Uberall F. Protein kinase C modulation. Semin Cancer Biol 1992;3:351-360.
41. Hofmann J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 1997;11:649-669.
42. Gordge P, and Ryves W. Inhibitors of protein kinase C. Cell Signal 1994;6:871-882.
43. Wilkinson SE, Hallam TJ. Protein kinase C: is its pivotal role in cellular activation over-stated? Trends Pharmacol Sci 1994; 15:53-57.
44. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39: 2664-2671.
45. Heath WF, Jirousek MR, McDonald III JH, Rito CJ. Macrocycle(s) containing a (bis)indolylmaleimide group are protein kinase C and isoenzyme selective, used to treat diabetes, ischemia, inflammation, CNS or cardiovascular disorders, or cancer. EP94308947.4 1995 1995.
46. Heath WF, Jirousek MR, McDonald III JH, Rito CJ. Isozyme selective Protein Kinase C inhibitors. US patent 5,552,396 1996.
47. Neel DA, Melikian-Badalian A, Baevsky M, et al. A novel series of isoform and kinase selective protein kinase C antagonists. Abstracts of the American Chemical Society National Meeting, 1995.
48. Neel DA, Melikian-Badalian A, Baevsky M, et al. Synthesis and SAR of protein kinase C (PKC) selective inhibitors: 14 membered bisindolylmaleimide macrocycles. American Chemical Society National Meeting, 1996.
49. Meier RW, Chen T, Matthews G, Niklaus G, Tobler A. The differentiation pathway of HL-60 cells is a model system for studying the specific regulation of some genes. Cell Growth Differ 1992;3:663-669.
50. Yoshida K, Murohashi I, Hirashima K. p53-independent induction of p21 (WAF1/CIP1) during differentiation of HL-60 cells by tumor necrosis factor alpha. Int J Hematol 1996; 65:41-48.
51. Sherr CJ. The ins and outs of RB: Coupling gene expression to the cell cycle clock. Trends Cell Biol 1994;4:15-18.
52. Koya D, Jirousek MR, Lin Y-W, Ishii H, Kuboki K, King GL. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-b, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100: 115-126.
53. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731
54. Mischak H, Pierce JH, Goodnight J, Kazanietz MG, Blumberg PM, Mushinski JF. Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-alpha and -delta and not by protein kinase C-beta II, -epsilon, -zeta, and -eta. J Biol Chem 1993;268:20110-20115.
55. Murray NR, Baumgardner GP, Burns DJ, Fields AP. Protein kinase C isotypes in human erythroleukemia (k562) cell proliferation and differentiation: Evidence that β2 protein kinase C is required for proliferation. J Biol Chem 1993; 268:15847-15853.
56. Woloschak G. Is PKC activation required for leukemia cell differentiation? Leuk Res 1997;21:411-414.
57. Wooten MW, Seibenhener ML, Soh Y. Expression of protein kinase C isoforms in HL60 and phorbol ester resistant HL525 cells. Cytobios 1993;76:19-29.
58. Kolesnick RN. Sphingomyelinase action inhibits phorbol ester-induced differentiation of human promyelocytic leukemic (HL-60) cells. J Biol Chem 1989;264:7617-7623.
59. Goss VL, Hocevar BA, Thompson LJ, Stratton CA, Burns DJ, Fields AP. Identification of nuclear b2-Protein Kinase C as a mitotic lamin kinase. J Biol Chem 1994;269: 19074-19080.
60. Kishimoto A, Mikawa K, Hashimoto K, et al. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J Biol Chem 1989; 264:4088-4092.
61. Savart M, Letard P, Bultel S, Ducastaing A. Induction of protein kinase C down-regulation by the phorbol ester TPA in a calpain/protein kinase C complex. Int J Cancer 1992;52: 399-403.
62. Han ZT, Tong YK, He LM, et al. 12-o-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci USA 1998;95: 5362-5365.
63. Han ZT, Zhu XX, Yang RY, et al. Effect of intravenous infusions of 12-o-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 1998;95:5357-5361.
64. Kowluru RA, Jirousek MR, Stramm L, Farid N, Engerrnan RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes 1998;47:464-469.
65. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-179.